晚期卵巢癌新辅助化疗的Meta分析

Neoadjuvant chemotherapy in advanced ovarian cancer:a Meta analysis of randomized controlled trials

目的:评价新辅助化疗对晚期卵巢癌患者总生存期及无进展生存期的影响,探讨新辅助化疗在晚期卵巢癌的应用价值。方法:计算机检索PubMed数据库、Med-line数据库、EMbas数据库、Cochrane Library数据库、万方数据库、中国学术文献总库(CNKI)、中国生物医学文献数据库(CBM),手工检索《中华妇产科杂志》,《中国实用妇科与产科杂志》,《实用妇产科杂志》,《生殖与避孕》,《现代妇产科进展》5本妇产科杂志。语言种类为中文和英文,网上检索时间不限。试验组行新辅助化疗,即以铂类为基础的化疗后行细胞减灭术;对照组行传统治疗,即细胞减灭术后行规范性化疗。结果:共纳入3篇文献,提取数据后,Review Manager5.0软件进行Meta分析,两组的总生存期合并后的RR值为0.96(95%CI,0.90～1.03),两组的无进展生存期合并后的RR值为1.00(95%Cl 0.93～1.09),森林图菱形均与垂直线相交。结论:新辅助化疗并未改善晚期卵巢癌患者的预后。

Objective：To evaluate whether neoadjuvant chemotherapy will improve progession free survival（PFS） and overall survival（OS） in advanced ovarian cancer patients.Methods：We search PubMed database,Medline database,EMbas database,Cochrane Library,WANFANG database,CNKI and CBM in the internet.We also hand-search 5 journals of Obstetrics and Gynecology（Chinese Journal of Obstetrics and Gynecology,Chinese Journal of Practical Gynecology and Obstetrics,Journal of Practical Obstetrics and Gynecology,Reproduction and Contraception,Progress in Obstetrics and Gynecology）.The experimental group accepted platinum-based adjuvant chemotherapy before cytoreductive surgery and the control group accepted primary cytoreductive surgery following adjuvant chemotherapy.Results：Totally 3 articles were included.Meta-analysis on the selected literature was processed by Revman 5.0.According to the results of fixed-effect model,the RR of OS was 0.96（95%CI,0.90~1.03）.Because there was heterogeneity in PFS,the result adopt random-effect model,the RR of PFS was 1.00（95%Cl 0.93~1.09）.Conclusion：Neoadjuvant chemotherapy don＇t improve the outcome for advanced ovarian cancer.